BioSpace News Archive

Mirati Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering.

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.rockwellmed.com, under the “Investors” section.

A key immune signal has a previously unknown role in turning off the immune system’s attack on pancreatic cancer cells, a new study finds.

ADVANZ PHARMA Corp. Limited announced changes to its board of directors that are consistent with the Company’s previously disclosed strategic focus on Western Europe.

Funds Will Be Used to Accelerate Commercialization of the ZAP-X Robotic Surgical Platform for Non-Invasive Treatment of Brain Tumors Affecting More Than 2 Million Cancer Patients Worldwide

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced the pricing of its public offering of 6,000,000 ordinary shares at a price to the public of $5.00 per share.

Capital to enable Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline development [08-January-2020] IRVINE, Calif. , Jan. 8, 2020 /PRNewswire/ -- Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the completion of $60 million in Series B financing. The financing was led by Vivo Capital an